Recent Advancements and Future Perspectives of Microalgae-Derived Pharmaceuticals.

Microalgal cells serve as solar-powered factories that produce pharmaceuticals, recombinant proteins (vaccines and drugs), and valuable natural byproducts that possess medicinal properties. The main advantages of microalgae as cell factories can be summarized as follows: they are fueled by photosynthesis, are carbon dioxide-neutral, have rapid growth rates, are robust, have low-cost cultivation, are easily scalable, pose no risk of human pathogenic contamination, and their valuable natural byproducts can be further processed. Despite their potential, there are many technical hurdles that need to be overcome before the commercial production of microalgal pharmaceuticals, and extensive studies regarding their impact on human health must still be conducted and the results evaluated. Clearly, much work remains to be done before microalgae can be used in the large-scale commercial production of pharmaceuticals. This review focuses on recent advancements in microalgal biotechnology and its future perspectives.

Integrating pyrolysis and ex-situ catalytic reforming by microwave heating to produce hydrocarbon-rich bio-oil from soybean soapstock.

The composite catalysts were synthesized with SiC powder and ZSM-5 and were characterized by Brunauer-Emmett-Teller, X-ray diffraction, thermogravimetric analysis, pyridine-infrared spectroscopy, and scanning electron microscopy. The catalysts showed a high heating rate and excellent catalytic performance for pyrolysis vapors, and the product fractional distribution and chemical compositions of bio-oil in a tandem system (microwave pyrolysis and microwave ex-situ catalytic reforming) was examined. Experimental results confirmed the quality of bio-oil produced by the microwave-induced catalytic reforming was better than that product through electric heating. Additionally, 36.94 wt% of bio-oil was obtained using the catalyst with 20%ZSM-5/SiC under the following conditions: feed-to-catalyst ratio, 2:1; pyrolysis temperature, 550 °C; and catalytic temperature, 350 °C. The selectivities of hydrocarbons reached up to 75.88%. After five cycles, the activity of the regenerated composite catalyst was retained at 95% of the original catalyst.

Identification and genetic characterization of avian-origin H3N2 canine influenza viruses isolated from the Liaoning province of China in 2012.

A total of 158 serum samples and 510 nasal swab specimens were collected between September 2010 and May 2012, from dogs exhibiting respiratory symptoms, in order to investigate the epidemiology of H3N2 canine influenza viruses (CIVs) in the Liaoning province of China. Serological surveillance demonstrated that 10.8 % (17/158) of serum samples were positive for H3N2 canine influenza. Two H3N2 influenza viruses, A/canine/Liaoning/27/2012 and A/canine/Liaoning/H6/2012, were isolated from pet dogs in 2012. Phylogenetic analysis indicated that the genes from these two viruses were closely related to those of avian-origin, H3N2 subtype CIVs from China and Thailand. Genetic analysis of eight genes revealed that these two H3N2 canine influenza isolates were highly similar (99.2-99.8 %) to the current common strains in Asia. Analysis of the genotype demonstrated that each gene of the two strains in this study had the same genotype (K, G, E, 3B, F, 2D, F, 1E) as those prevalent in H3N2 CIVs. Our findings further confirm that avian-origin H3N2 canine influenza has become established in China. Conducting extensive serological and epidemiological surveillance is necessary to develop an effective vaccine against this disease.